EWM
HRTX icon

Evermay Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Evermay Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$130 – 609
2025
Q4 		$130 Hold
100
– – ﹤0.01% 559
2025
Q3 		$126 Hold
100
– – ﹤0.01% 539
2025
Q2 		$207 Hold
100
– – ﹤0.01% 549
2025
Q1 		$220 Hold
100
– – ﹤0.01% 562
2024
Q4 		$153 Hold
100
– – ﹤0.01% 554
2024
Q3 		$199 Hold
100
– – ﹤0.01% 577
2024
Q2 		$350 Hold
100
– – ﹤0.01% 582
2024
Q1 		$277 Hold
100
– – ﹤0.01% 586
2023
Q4 		$170 Hold
100
– – ﹤0.01% 666
2023
Q3 		$103 Hold
100
– – ﹤0.01% 552
2023
Q2 		$116 Hold
100
– – ﹤0.01% 546
2023
Q1 		$151 Hold
100
– – ﹤0.01% 525
2022
Q4 		$250 Hold
100
– – ﹤0.01% 539
2022
Q3 		$0 Hold
100
– – ﹤0.01% 528
2022
Q2 		$0 Hold
100
– – ﹤0.01% 536
2022
Q1 		$1K Hold
100
– – ﹤0.01% 504
2021
Q4 		$1K Hold
100
– – ﹤0.01% 490
2021
Q3 		$1K Hold
100
– – ﹤0.01% 438
2021
Q2 		$2K Buy
+100
New +$1.59K ﹤0.01% 480

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Evermay Wealth Management's HRTX Position: Q1 2026 in Review

Evermay Wealth Management sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 100 shares — an estimated $130 sold.

Evermay Wealth Management first reported a position in HRTX in Q2 2021 and held it in 19 quarters. The position peaked at $2K in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Evermay Wealth Management reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Evermay Wealth Management sold 100 Heron Therapeutics shares in Q1 2026, an estimated $130.
  • Evermay Wealth Management first reported a position in Heron Therapeutics in Q2 2021 and held it in 19 quarters.
  • Evermay Wealth Management's Heron Therapeutics position peaked at $2K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Evermay Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.